Relevance of the development of hard gelatin capsules for the treatment of raynaud's syndrome

Abstract

Raynaud's syndrome (RS) is episodes of transient digital ischemia due to vasospasm of digital arteries, precapillary arterioles and cutaneous arteriovenous shunts under the influence of cold temperature and emotional stress. The clinical significance of RS is due to its high prevalence in the population and frequent association with other, often life-threatening, diseases and conditions. RS occurs in 3-5% of the population, most often manifesting itself at the age of 20-40 years, especially in women, who are 2-9 times more likely to suffer than men. In the elderly (over 60 years of age), the prevalence is much lower (0.1-1%). The primary syndrome, as an independent disease, accounts for more than 80 % of cases, while the secondary syndrome is a complication of other pathologies and occurs in 20 % of cases. Raynaud's syndrome develops against the background of other diseases or external factors and can lead to more serious complications (for example, ulcers on the fingers, gangrene)